News
Glaxo to Get Up to $200 Million From U.S. for Biothreat Research
June 1, 2013 /
GlaxoSmithKline Plc (GSK), the U.K.’s largest drugmaker, will work with the U.S. government to develop antibiotics for resistant infections and bioterrorist threats in an agreement valued at as much as $200 million.
By Makiko Kitamura and Olivia Sterns
MATR Supporters (view all)
Posted in: Biotech
Sorry, we couldn't find any posts. Please try a different search.